Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
← catalyst calendarNCT07770828 · readout in 711 d
Sponsored by Ocugen (industry) · OCGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
237estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-11 | actual | When the study began enrolling |
| Primary completion | 2028-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dry Age-related Macular Degeneration
Intervention
- Biological: OCU410
Primary outcome
what the primary-completion date above is the date OFRate of change (slope) of square root-transformed GA lesion area from baseline to Month 12
measured Month 12
Permalink · OCGN's whole pipeline · Catalyst calendar · Every registered study · What changed